Patient Recruitment & Retention Strategy & ICF Governance Director (Biotech / Oncology)
Exelixis
Summary
Leads the implementation of the recruitment and retention strategy while ensuring adherence to global requirements and guidelines across our informed consent forms and clinical trials. Leads a cross-functional governance team and collaborates effectively with internal and external parties (CROs, vendors and sites) to ensure that clinical trials meet their enrollment and retention goals. The responsibilities of this role are executed across all programs, phases and therapeutic areas in clinical trials at Exelixis.
Job description
Summary/Job Purpose
Leads the implementation of the recruitment and retention strategy while ensuring adherence to global requirements and guidelines across our informed consent forms and clinical trials. Leads a cross-functional governance team and collaborates effectively with internal and external parties (CROs, vendors and sites) to ensure that clinical trials meet their enrollment and retention goals. The responsibilities of this role are executed across all programs, phases and therapeutic areas in clinical trials at Exelixis.
Essential Duties/Responsibilities
- Partners cross-functionally and with study teams to execute the methodology for delivering the portfolio of studies within the defined budgets and timelines.
- Development of enabling policies and procedures aligned with emerging external laws and guidance (e.g., ICH E6R3 Guidance)
- Utilization of key data assets
- Creation of targets or key performance indicators
- Methods to enable appropriate and durable engagement in under-represented people including, but not limited to, the usage of decentralized/direct-to-patient models.
- Lead informed consent cross-functional governance team and informed consent reviews.
- Evaluate and update generic informed consent templates to ensure alignment with latest global guidance and requirements.
- Work with CROs to understand CRO processes and train on Exelixis process and templates.
- Maintain ICH/GCP compliance, ensuring quality in every element of our informed consent process and forms.
- Collaborate with Study Delivery Leads to ensure timelines are met.
- Work with internal and external stakeholders to develop tactics in reaching recruitment and retention goals, including more patient friendly study documents.
- Develop a repository of information gathered from informed consent global submissions to integrate into updated templates in an effort to expedite study timelines.
- Participate in health authority inspections and activities as appropriate.
- Support Exelixis Public Relations and external corporate giving, or Employee Resource Group (ERG) initiatives (e.g., community service).
- Performs other duties as assigned
- Complies with all policies and standards
Supervisory Responsibilities
None.
Education/Experience/Knowledge/Skills & Abilities
Education
- BS/BA degree in Science, Business or related discipline and a minimum of 13 years of related experience; or,
- MS/MA degree in Science, Business or related discipline and a minimum of 11 years of related experience; or,
- Equivalent combination of education and experience.
- May require certification in assigned area.
Experience
- Typically requires at least 6 years of experience in global informed consent process and forms.
- Experience across different tumor indications and clinical trial phases.
- Experience in electronic data management.
- Experience reducing both patient and site burden during clinical trials.
- Experience partnering closely and building relationships with sites is a plus.
Knowledge, Skills and Abilities
Required:
- Leadership and collaboration in complex matrix run organizations.
- Ability to think through, provide solutions and innovate to recruit and retain participants for clinical trials.
- Knowledge of GCP and regulatory requirements related to conducting clinical trials worldwide.
- Ability to identify and implement methods, techniques, procedures and evaluation criteria to achieve results.
- Ability to prioritize and perform a variety of complicated tasks with a wide degree of creativity and latitude.
- Applies strong analytical and business communication skills.
Requirements
- BS/BA degree in Science, Business or related discipline and a minimum of 13 years of related experience; or, MS/MA degree in Science, Business or related discipline and a minimum of 11 years of related experience; or, Equivalent combination of education and experience.
- Typically requires at least 6 years of experience in global informed consent process and forms.
- Experience across different tumor indications and clinical trial phases.
- Experience in electronic data management.
- Experience reducing both patient and site burden during clinical trials.
- Leadership and collaboration in complex matrix run organizations.
- Ability to think through, provide solutions and innovate to recruit and retain participants for clinical trials.
- Knowledge of GCP and regulatory requirements related to conducting clinical trials worldwide.
- Ability to identify and implement methods, techniques, procedures and evaluation criteria to achieve results.
- Ability to prioritize and perform a variety of complicated tasks with a wide degree of creativity and latitude.
- Applies strong analytical and business communication skills.
Benefits
- 401(k) Matching
- Medical, Dental & Vision
- Life & Disability Insurance
- Flexible Spending Accounts
- Discretionary Annual Bonus
- Company Stock Purchase
- Long-Term Incentives
- 15 Vacation Days
- 17 Paid Holidays
- Up to 10 Sick Days
Company overview
Exelixis, Inc. is an oncology-focused biotechnology company headquartered in Alameda, California, that specializes in the discovery, development, and commercialization of innovative cancer treatments. Founded in 1994, the company has evolved into a multi-platform cancer organization with a proven track record in the challenging biotech sector. Exelixis is best known for its flagship molecule cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET, which has led to several approved drugs for difficult-to-treat cancers. The company's portfolio includes four approved drugs, with two derived from cabozantinib, and it maintains a robust pipeline of next-generation cancer treatments. With approximately 1,500 employees across five continents, Exelixis operates as a publicly traded company (NASDAQ: EXEL) and has established strategic alliances with major pharmaceutical and biotechnology partners. The company's mission centers on transforming science into new treatments that give cancer patients and their families hope for the future, with every employee united in this ambitious cause.